Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject

• US 20100035855A1
• Filed: 08/28/2009
• Published: 02/11/2010
• Est. Priority Date: 07/24/2008
• Status: Abandoned Application

• Current Assignee: Searete LLC (Intellectual Ventures LLC)
• Original Assignee: Searete LLC (Intellectual Ventures LLC)
• Inventors: Ishikawa, Muriel Y., Wood, Lowell L. JR., Rivet, Dennis J., Hyde, Roderick A., Sweeney, Elizabeth A., Wood, Victoria Y.H., Leuthardt, Eric C.
• Application Number:
  US12/584,046
• Publication Number:
  US 20100035855A1
• Time in Patent Office: Days
• US Class Current: 514/182
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/415 1,2-Diazoles
• CPC Class Codes: A61K 31/423 condensed with carbocyclic rings
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

A method for treating cardiovascular disease in a mammalian subject includes providing to the subject at least one treatment regimen including at least one estrogen receptor modulator, wherein the at least one treatment regimen is determined based on the APOE allelic profile in the subject, and based on the steroid hormone levels prior to disease diagnosis and on current steroid hormone levels in the subject.

Claims

1-34. -34. (canceled)

35. A system comprising:

a signal-bearing medium including,

one or more instructions for determining at least one treatment regimen including at least one estrogen receptor modulator for a mammalian subject, wherein the at least one treatment regimen is determined based on the APOE allelic profile in the mammalian subject, and wherein the mammalian subject has at least one reduced steroid hormone level compared to a steroid hormone level prior to diagnosis of a cardiovascular disease or condition.

36. The system of claim 35, wherein the mammalian subject'"'"'s APOE allelic profile is at least one of APOE ε

2 positive and APOE ε

3 positive.

37. The system of claim 36, wherein the at least one estrogen receptor modulator includes at least one selective estrogen receptor α

agonist.

38. The system of claim 36, wherein the mammalian subject'"'"'s APOE allelic profile is ε

4 negative.

39. The system of claim 35, further including one or more instructions for determining the at least one treatment regimen including at least one replacement therapy for one or more steroid hormones or metabolites or modulators thereof.

40. The system of claim 39, wherein the at least one treatment regimen including the least one replacement therapy is configured to increase levels of one or more of an estrogen and a progestogen, or metabolites or modulators thereof.

41. The system of claim 37, wherein the at least one selective estrogen receptor α

agonist includes 17β

-estradiol, propylpyrazole triol, or 3,17-dihydroxy-19-nor-17α

-pregna-1,3,5 (10)triene-21,16α

-lactone.

42. The system of claim 35, wherein the mammalian subject'"'"'s APOE allelic profile is ε

4 positive.

43. The system of claim 42, wherein the at least one estrogen receptor modulator includes at least one selective estrogen receptor β

agonist.

44. The system of claim 39, wherein the at least one treatment regimen includes the at least one replacement therapy is configured to increase levels of one or more of an estrogen and a progestogen, or metabolites or modulators thereof.

45. The system of claim 44, wherein the at least one treatment regimen includes replacement therapy with one or more of an estrogen and a progestogen.

46. The system of claim 43, wherein the at least one selective estrogen receptor β

agonist includes diarylpropionitrile, ERB-041, WAY-202196, WAY-214156 (2,8-dihydroxy-6H-dibenzo[c,h]chromene-4,12-dicarbonitrile), or 8-vinylestra-1,3,5 (10)-triene-3,17β

-diol.

47. The system of claim 35, wherein the at least one estrogen receptor modulator is configured to maintain the mammalian subject'"'"'s one or more steroid hormones or metabolites or modulators thereof at substantially physiological cyclic levels, and the at least one estrogen receptor modulator is in an amount effective to reduce cardiovascular disease or condition or alleviate symptoms thereof in the mammalian subject.

48. The system of claim 35, wherein the mammalian subject is female.

49. The system of claim 47, wherein the mammalian subject is perimenopausal or postmenopausal.

50. The system of claim 47, wherein the at least one treatment regimen is determined at least in part based on the premenopausal cyclic steroid hormone levels in the mammalian subject and on current cyclic steroid hormone levels in the mammalian subject.

51. The system of claim 35, wherein the mammalian subject is male.

52. The system of claim 35, further including one or more instructions for inputting information associated with the steroid hormone levels prior to disease diagnosis and on current steroid hormone levels in the mammalian subject.

53. The system of claim 35, wherein the at least one treatment regimen is configured to maintain a substantially physiological cyclic level of one or more steroid hormones prior to disease diagnosis in the mammalian subject in need thereof, and the at least one treatment regimen is in an amount effective to reduce cardiovascular disease or condition or alleviate symptoms thereof in the mammalian subject.

54. The system of claim 35, wherein the signal bearing medium includes a computer readable medium.

55. The system of claim 35, wherein the signal bearing medium includes a recordable medium.

56. The system of claim 35, wherein the signal bearing medium includes a communications medium.

57. A device comprising:

a system including a signal-bearing medium including,

one or more instructions for determining at least one treatment regimen including at least one estrogen receptor modulator for a mammalian subject, wherein the at least one treatment regimen is determined based on the APOE allelic profile in the mammalian subject, and wherein the mammalian subject has at least one reduced steroid hormone level compared to a steroid hormone level prior to disease diagnosis.

58. The device of claim 57, wherein the mammalian subject'"'"'s APOE allelic profile is at least one of APOE ε

2 positive and APOE ε

3 positive.

59. The device of claim 58, wherein the at least one estrogen receptor modulator includes at least one selective estrogen receptor α

agonist.

60. The device of claim 58, wherein the mammalian subject'"'"'s APOE allelic profile is ε

4 negative.

61. The device of claim 57, wherein the mammalian subject'"'"'s APOE allelic profile is ε

4 positive.

62. The device of claim 61, wherein the at least one estrogen receptor modulator includes at least one selective estrogen receptor β

agonist.

63. The device of claim 57, further including one or more instructions for determining the at least one treatment regimen including at least one replacement therapy for one or more steroid hormones or metabolites or modulators thereof.

64. The device of claim 63, wherein the at least one treatment regimen including the least one replacement therapy is configured to increase levels of one or more of an estrogen and a progestogen or metabolites or modulators thereof.

65. The device of claim 64, wherein the at least one treatment regimen includes replacement therapy with one or more of an estrogen and a progestogen.

66. The device of claim 57, wherein the mammalian subject is female.

67. The device of claim 66, wherein the mammalian subject is perimenopausal or postmenopausal.

68. The device of claim 66, wherein the at least one treatment regimen is determined based on the premenopausal cyclic steroid hormone levels in the mammalian subject and on current cyclic steroid hormone levels in the mammalian subject.

69. The device of claim 57, wherein the mammalian subject is male.

70-82. -82. (canceled)

83. A system comprising:

circuitry for determining at least one treatment regimen including at least one estrogen receptor modulator for a mammalian subject, wherein the at least one treatment regimen is determined based on the APOE allelic profile in the mammalian subject, and wherein the mammalian subject has at least one reduced steroid hormone level compared to a steroid hormone level prior to diagnosis of a cardiovascular disease or condition.

84. The system of claim 83, wherein the mammalian subject'"'"'s APOE allelic profile is at least one of APOE ε

2 positive and APOE ε

3 positive.

85. The system of claim 84, wherein the at least one estrogen receptor modulator includes at least one selective estrogen receptor α

agonist.

86. The system of claim 84, wherein the subject'"'"'s APOE allelic profile is ε

4 negative.

87. The system of claim 83, wherein the mammalian subject'"'"'s APOE allelic profile is ε

4 positive.

88. The system of claim 87, wherein the at least one estrogen receptor modulator includes at least one selective estrogen receptor β

agonist.

89. The system of claim 83, further including circuitry for determining the at least one treatment regimen including at least one replacement therapy for one or more steroid hormones or metabolites or modulators thereof.

90. The system of claim 89, wherein the at least one treatment regimen including the least one replacement therapy is configured to increase levels of one or more of an estrogen and a progestogen, or metabolites or modulators thereof.

91. The system of claim 90, wherein the at least one treatment regimen includes replacement therapy with one or more of an estrogen and a progestogen.

92. The system of claim 83, further including circuitry for inputting information associated with the steroid hormone levels prior to disease diagnosis and on current steroid hormone levels in the mammalian subject.

93. The system of claim 83, wherein the at least one treatment regimen is configured to maintain a substantially physiological cyclic level of one or more steroid hormones prior to disease diagnosis in the mammalian subject in need thereof.

94. The system of claim 83, wherein the mammalian subject is female.

95. The system of claim 94, wherein the mammalian subject is perimenopausal or postmenopausal.

96. The system of claim 94, wherein the at least one treatment regimen is determined based on the premenopausal cyclic steroid hormone levels in the mammalian subject and on current cyclic steroid hormone levels in the mammalian subject.

97. The system of claim 83, wherein the mammalian subject is male.

211. The system of claim 83, wherein the at least one estrogen receptor modulator is configured to maintain the mammalian subject'"'"'s one or more steroid hormones or metabolites or modulators thereof at substantially physiological cyclic levels, and the at least one estrogen receptor modulator is in an amount effective to reduce cardiovascular disease or condition or alleviate symptoms thereof in the mammalian subject.

212. The system of claim 83, further including one or more instructions for inputting information associated with the steroid hormone levels prior to disease diagnosis and on current steroid hormone levels in the mammalian subject.

213. The system of claim 83, wherein the at least one treatment regimen is configured to maintain a substantially physiological cyclic level of one or more steroid hormones prior to disease diagnosis in the mammalian subject in need thereof, and the at least one treatment regimen is in an amount effective to reduce cardiovascular disease or condition or alleviate symptoms thereof in the mammalian subject.

98-210. -210. (canceled)